Merck’s Q3 results beat estimates; sales boosted by oncology and vaccines

[anonymous]

Merck surpassed analysts’ expectations for revenue and earnings in the third quarter of 2019, sending the shares climbing 2.5% in premarket hours on Tuesday.
Worldwide sales rose 15% year-over-year to $12.4 billion, beating estimates of $11.6 billion. Excluding foreign exchange impacts, sales grew 16%. Sales growth was driven by strength in oncology and human health vaccines. Source

 

[anonymous]

Merck surpassed analysts’ expectations for revenue and earnings in the third quarter of 2019, sending the shares climbing 2.5% in premarket hours on Tuesday.
Worldwide sales rose 15% year-over-year to $12.4 billion, beating estimates of $11.6 billion. Excluding foreign exchange impacts, sales grew 16%. Sales growth was driven by strength in oncology and human health vaccines. Source

It's all just "voodoo" economics and creative accounting of course...

As those way Fabs once said, "Strawberry Fields - Nothing is real."

Major truth drop in that tune...

 

[anonymous]

It's all just "voodoo" economics and creative accounting of course...

As those way Fabs once said, "Strawberry Fields - Nothing is real."

Major truth drop in that tune...

Steglatro predominantly led to Merck beating estimates!! What a drug! As stated Merck is rethinking its downsizing due to Steglatro ‘s stupendous sales

 

[anonymous]

Announced today!! Steglatro has taken over as the number 1 SGLT2 prescribed. What a accomplishment!!!